Identification of Selective CYP3A7 and CYP3A4 Substrates and Inhibitors Using a High-Throughput Screening Platform

Area of Science:

• Pharmacology
• Biochemistry
• Drug Metabolism

Background:

• Cytochrome P450 (CYP) 3A7 is a significant xenobiotic metabolizing enzyme in early human development and in specific adult populations.
• Limited characterization and lack of regulatory guidance for CYP3A7 complicate drug-drug interaction (DDI) assessments.
• Understanding CYP3A7's role is crucial for predicting drug efficacy and safety.

Purpose of the Study:

• To identify selective inhibitors and substrates for CYP3A7.
• To compare CYP3A7 activity with CYP3A4, another major drug-metabolizing enzyme.
• To establish a dataset for predictive modeling of drug metabolism and interactions.

Main Methods:

• Screening of approximately 5,000 compounds using P450-Glo CYP3A7 and CYP3A4 enzyme assays.
• Metabolic stability assays on a subset of 1,000 compounds.
• Molecular docking for evaluating potential CYP3A7 inhibitors like Halometasone.

Main Results:

• Identification of chemical features contributing to CYP3A7 selectivity.
• Discovery of twenty-two CYP3A7-selective substrates over CYP3A4.
• Demonstration of CYP3A7's ligand promiscuity, similar to CYP3A4.
• Halometasone identified as a potential CYP3A7-selective inhibitor.

Conclusions:

• Established a comprehensive dataset for CYP3A7 research and predictive modeling.
• Highlighted the need for further investigation into CYP3A7's role in drug metabolism and DDI.
• Provided insights into identifying CYP3A7-specific molecules for safer drug development.